作者: Simone Dario Scilabra , Armando Rossello , Elisa Nuti , Doretta Cuffaro , Simone Bonelli
DOI: 10.3390/MOLECULES26040944
关键词: Disease 、 Context (language use) 、 Disintegrin 、 Computational biology 、 Matrix metalloproteinase 、 Transmembrane protein 、 Tumor necrosis factor alpha 、 In vivo 、 Immune system 、 Biology
摘要: For decades, disintegrin and metalloproteinase 17 (ADAM17) has been the object of deep investigation. Since its discovery as tumor necrosis factor convertase, it considered a major drug target, especially in context inflammatory diseases cancer. Nevertheless, development drugs targeting ADAM17 harder than expected. This generally due to multifunctionality, with over 80 different transmembrane proteins other α (TNF) being released by ADAM17, structural similarity metalloproteinases. review provides an overview roles disease effects ablation number vivo models pathological conditions. Furthermore, here, we comprehensively encompass approaches that have developed accomplish selective inhibition, from newest non-zinc-binding synthetic inhibitors exploitation iRhom2 specifically target immune cells.